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Abstract
In this report from the 1st European Conference of the European Science Foundation
Programme on Functional Genomics, we provide coverage of the high-proﬁle plenary
talks and a cross-section of the many presentations in the disease analysis symposia
and functional genomics technologies workshops. Copyright  2003 John Wiley &
Sons, Ltd.
Plenary presentations
Leena Peltonen (National Public Health Insti-
tute, Finland) spoke about what can be learned
from rare and common disease genes in a genetic
isolate. Diseases can be more prevalent in one pop-
ulation, due to a founder effect, when all cases
are derived from one original carrier in a small
population. The length of an interval of linkage
disequilibrium relates to the age of a mutation; in
Finnish populations, some regions of LD contain-
ing disease genes are 13 cM long; they are rela-
tively young. Using a shared haplotype approach
works well in a founder situation. They used it
to narrow down the critical region for progressive
myeloclonus epilepsy (PME). Using LD allows the
use of a relatively sparse genetic map to study
monogenic disorders, which is more cost- and time-
effective. Her group has mapped ∼20 Finnish rare
monogenic diseases using this approach, and in
several cases a gene has been cloned. They aim
to move on to provide diagnostic tests and carrier
screening programmes and have made a chip array
of all of these mutations to allow genotyping.
In the case of complex traits, the advantage of
isolated populations is that they have a higher
degree of genetic homogeneity. There are fewer
mutations, and they are easier to identify. There is
also a higher degree of environmental homogeneity
and lifestyles, diet and culture are far more similar.
They have made scans and identiﬁed loci in 13
complex diseases, most of which have been veriﬁed
in other populations. They have found that the idea
that once you know where an LD block is you will
only need one SNP does not hold true. They do not
know how many SNPs per block will be needed,
but they often ﬁnd that it is more than two.
Hans Lehrach (Max-Planck-Institute for
Molecular Genetics, Germany) used chromosome
21 to illustrate a systems biology approach
to investigating disease processes. Most current
databases focus on either a single organism or
one type of information, e.g. protein structure.
The Genome Matrix (www.genome-matrix.org)
is a new database/interface that will integrate all
the information available for a given gene. Inputs
include whole-mount in situ expression data for all
genes on chromosome 21 and an expression map
for all these genes in the mouse on post-natal day 2.
In due course, the model will include information
from knockout studies in model organisms, RNAi
experiments and even clinical information, such as
Copyright  2003 John Wiley & Sons, Ltd.550 Meeting Report
chest X-rays from a patient with a mutation in the
gene being studied.
Ian Dunham (Wellcome Trust, Sanger Insti-
tute, UK) gave a lovely talk on studying the
structural and functional properties of the human
genome through the microcosm of chromosome
22. The idea is to combine detailed annotation of
both gene and protein expression with analysis of
replication timing. DNA is replicated from multiple
origins but it is not known whether this is initiated
stochastically on open regions of chromatin and
then progresses to euchromatin, or whether there is
an underlying programme.
Mathias Uhlen (Royal Institute of Technology,
Sweden) described an ambitious project to create
afﬁnity reagents for all known human gene prod-
ucts. Most of the assays are performed on denatured
tissue samples, therefore polyclonal antibodies are
preferred, but these need to be complemented with
monoclonal antibodies to ensure speciﬁcity and
continued supplies of the reagents. Two of the chal-
lenges to be met are the difﬁculty of making human
proteins in Escherichia coli and the problem of
antibody cross-reactivity. The Swedish scheme is
based on protein epitope signature tags (PrEST). A
bioinformatic tool searches each full-length ORF
for sequences with low homology to the rest of the
genome and designs PCR primers automatically,
avoiding transmembrane domains. The PCR prod-
ucts are cloned and expressed in E. coli and the
puriﬁed proteins are used to generate antibodies in
chickens. The antibodies are used to screen an array
of human tissue samples for detailed histopatho-
logical analysis on a large scale. This often reveals
complex expression patterns, with a protein show-
ing up in a variety of tissues.
The Human Proteome Resource, which was
launched in January 2003, plans to isolate the
proteins from 14000 genes in 4 years. Arrays will
be prepared from 48 human tissues, the 18 most
frequent cancers that occur in Western populations
and 60 human cell lines. The aim is to prepare 700
high-resolution images for every protein, showing
its relative expression down to the subcellular level
in these samples.
Kelly Frazer (Perlegen, USA) described the use
of high-density oligonucleotide arrays in studying
mammalian genomics. They have over 13 billion
25-mer probes, representing the non-repetitive frac-
tion of the human genome, on a series on high-
density microarrays.
They have used 248000 long-range PCRs to
amplify single copies of human genome sequences
and have identiﬁed over 1.7 million SNPs. These
have been used to deﬁne 175309 haplotype blocks
(where the deﬁnition of a haplotype block is one
in which 80% of human chromosomes looked at
must have one of three patterns).
In comparisons with non-human primates, they
found that human and chimp long-range PCR prod-
ucts are generally the same size but that some
deletions and insertions occur. A more detailed
comparison revealed that the deletions comprise
varying amounts of unique and repetitive sequences
and that some regions have undergone genomic
rearrangement. Using the orang utan as an out-
group, they found insertions and deletions in both
the human and chimp genomes and that the major-
ity of rearrangements were randomly distributed.
Comparing a region of human chromosome 21
with six other mammalian genomes, they found
sequences conserved in all mammals (common),
sequences conserved in three or more mam-
mals (restricted), and sequences conserved only
between humans and one other species (uniquely
conserved). They believe that the common and
restricted sets of genes are actively conserved,
whereas the uniquely conserved genes could sim-
ply be the result of evolutionary proximity. 16%
of the sequence was conserved between human
and some mammals, of which 25% was ‘uniquely
conserved’, 50% was conserved in restricted sets
and 25% was common. This indicates that ∼11%
of human genome sequence is actively conserved,
which is much more than is generally recognized.
To see whether any of the elements in the restricted
class were functional, they identiﬁed those ele-
ments that were present in human and some other
mammals and absent in chimpanzee. Transfection
analyses showed that these conserved elements do
have functional consequences and therefore may be
involved in expression differences between species.
Many of the diseases that have the greatest
impact on public health are complex disorders that
show non-Mendelian inheritance. Jurg Ott (Rock-
efeller University, New York) discussed associ-
ation analysis for the identiﬁcation of multiple
susceptibility loci in such traits. Linkage analysis
emphasizes tracing a disease and a marker being
inherited together. For linkage disequilibrium to
fall to 50%, one needs SNPs 80 kb apart, which
is a very small distance for geneticists, but still
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means that 20000 SNPs are required to cover the
genome. Haplotype blocks may mean that fewer
SNPs may be sufﬁcient; however, genome-wide
association studies are still expensive. Association
analysis is a more powerful technique than linkage
analysis when looking for weak alleles. In case-
control association studies, a 2 × 2 matrix is plotted
of two alleles in cases vs. controls and the χ2 value
indicates the strength of the association. SNPs with
the highest value for χ2 are taken to be the most
signiﬁcant. For a speciﬁc tissue, gene expression
is compared in cases vs. controls or in normal vs.
diseased tissue, e.g. psoriasis. The values of χ2 are
then summed for particular groups, e.g. the ﬁve
strongest markers. The p values for these sums
decrease to a minimum then increase again as the
size of the group increases. SNPs that are close to
the disease gene increase the value of the associ-
ation, but SNPs that are further away simply add
noise. Therefore, the smallest p value is the statis-
tic of interest. This technique was applied to the
analysis of candidate genes in 779 patients with
heart disease who underwent angioplasty, compar-
ing those who underwent restenosis with those who
did not. The technique provided an answer statis-
tically when normal analysis had failed to get a
result. The method can also be used to analyse
microarray data and Jurg Ott is starting to extend it
to analyse interaction data. Alternative approaches
include data mining and combinatorial partitioning.
Klaus Lindpaintner (Hoffmann-La-Roche,
Switzerland) spoke about the impact of genetics
and genomics on drug discovery and development.
First, he explained how he sees pharmacogenomics,
which concerns many compounds and one
genome, and pharmacogenetics, which concerns
one compound and many genomes. He pointed
out that drugs are a special case of the
gene–environment interaction, which may be
particularly sensitive to genetic background. There
are two distinct entities in pharmacogenetics: the
classical, which is related only to drug action,
to the absorption, metabolism and elimination of
drugs; and the pathology-related, which relates
to the underlying disease pathology, a molecular
differential diagnosis. These are fundamentally
different concepts but both lead to stratiﬁcation of
patients based on a marker.
He is concerned at the lack of systematology
and metrics in pharmacogenetics, and proposed
some ideas for this, including the assessment of
sensitivity and speciﬁcity of tests, and the positive
and negative predictive values of tests. The TPMT
test, for example, can give negative results for some
patients who then go on to have side effects.
He feels that pharmacogenetics is likely to
enhance the efﬁcacy of drugs, and he does see a
role in diagnosis and prognosis, but he feels that it
is less likely to contribute signiﬁcantly to the avoid-
ance of adverse events. The majority of adverse
reaction deaths are due to prescription errors, which
are not genetically controlled. However, the FDA is
happy for drugs to ‘do better’ and will now permit
statements such as ‘patients with marker X have a
six times higher risk of adverse effects’.
Jan van Oostrum (Novartis, Switzerland)
explained that the role of the Functional Genomics
team at Novartis is to identify the cause of dis-
ease and to translate that genomic discovery into
drug discovery. The therapeutic areas they are
working on include Alzheimer’s disease, cancer
and chronic pain. They take a multidisciplinary
approach, including bioinformatics, model organ-
isms, pathway studies, antisense oligos and RNAi,
and use a range of functional genomics technolo-
gies, such as arrays and proteomics. They have an
in-house cDNA collection of 28000 predicted full-
length cDNAs with very low redundancy, which
they have arrayed. They use antisense and RNAi to
verify their understanding of the effects of genes of
interest, and their proteomics studies use a range of
methods, including 2DGE, SELDI and interaction
analyses.
Georg Feger (Serono, Switzerland) spoke about
a high throughput functional analysis of the secre-
tome. Their approach is to identify the ‘actors’ in
the process and demonstrate that they have a phar-
macological role. They are interested in the areas
of reproductive health, autoimmunity, metabolism,
cancer, ﬁbrosis and neurology. The ‘secretome’,
all of the cell-surface and secreted proteins, is a
source of therapeutic proteins. They have used a
range of bioinformatic approaches to identify all
of the human secreted proteins, which represent
∼10% of all proteins. The cDNAs of these genes
are then transiently expressed in mammalian cells
and puriﬁed (these can be kept as frozen stocks for
∼1 year). They then study these in vitro using 50
validated high-throughput cell-based assays (with
varying levels of complexity). This approach iden-
tiﬁed 100 potentials, which were narrowed down
to 10 valid candidates (since the therapeutics are
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endocrine, they need to be active in vivo). From
their assay set, they look for genes showing simi-
lar patterns of results to infer related function for
genes of unknown function, and then conﬁrm these
inferences using more detailed analyses.
Disease analysis symposia
Infection and host–parasite interaction
Peter Jungblut (Max-Planck-Institute of Infec-
tion Biology, Germany) spoke about his group’s
efforts to elucidate the proteomes of microor-
ganisms. In proteomics, an important goal is to
increase the number of detectable proteins; he out-
lined various technical reﬁnements that his group
and others have made, noting that the use of com-
plementary technologies, such as 2D gels and ICAT
can be very useful. In their hands, these two tech-
niques ﬁnd only a small proportion of proteins
in common, but do show matching quantitation,
in those cases where all of the spots on the 2D
gel that come from the protein of interest can
be accounted for. They have detected ∼20% of
the proteins of Helicobacter pylori, whereas in
Mycobacterium tuberculosis, they have only iden-
tiﬁed ∼10% of the 350 proteins; they hope to raise
this to 30% using the ICAT approach. They have
also made comparisons between non-virulent and
virulent mycobacteria, comparing M. bovis BCG
Chicago and M. tuberculosis H37Rv revealed six
new ORFs and 32 spots unique to the virulent
strains. The data from all of their studies, which
cover 10 microorganisms and some eukaryote tis-
sues, are available in a relational database from:
http://www.mpiib-berlin.mpg.de/2D-PAGE.
Rino Rappuoli (Chiron, Italy) presented a
genome-based approach to new vaccines. They
are working to develop vaccines against meningo-
coccus; this bacterium causes 350000 cases/year,
35000 of which are fatal. Although there is a long
chain polysaccharide vaccine for meningococcus C,
this is not possible for the B type, as its capsular
polysaccharide is identical to a human one, so it
is recognized as ‘self’. A membrane protein, PorA,
has been used as a target, but due to the variabil-
ity of this protein, the vaccine is strain-speciﬁc.
His team have collaborated with TIGR and Oxford
University to sequence the genome of Neisseria
meningitidis, with a view to aiding vaccine design.
This resulted in 600 potential vaccine candidates,
350 of which they have successfully expressed in
E. coli. Puriﬁcation of the proteins, followed by
immunization of mice and sera testing, success-
fully identiﬁed 91 novel surface-exposed proteins,
of which 28 showed bactericidal activity. To avoid
producing a strain-speciﬁc vaccine, they looked for
those proteins that were conserved across strains;
this reduced the list to ﬁve vaccine candidates,
which have now gone into trials. He feels that this
approach has been very productive and plans to
apply it to other pathogens.
Neil Hall (Wellcome Trust Sanger Institute,
UK) described the insights into antigenic variation
in malaria that have been afforded by the recently
completed genome sequences of Plasmodium falci-
parum and P. yoelii and the other related genomes
that are in progress.
Christoph Dehio (Basel, Switzerland) descri-
bed studies of the expression of Bartonella
henselae genes, and human genes, during infection,
done in collaboration with Siv Andersson’s group,
who sequenced the genome of this bacterium.
Bacterial genes induced during infection include
transport and secretion factors, including the type
IV secretion system, which mediates most of the
effects that the vir genes have on endothelial
cells. Looking at the expression of human genes
in the endothelial cells infected with wild-type
or vir mutant bacteria showed that about 10%
of the genes on the array were affected after
6 h (early infection) and just over twice as many
were affected at 30 h (well-established infection).
Some genes were more strongly induced by the
vir mutant infection, implying that they could be
repressed by the vir pathway, whereas others were
more strongly induced by the wild-type infection,
which could indicate that they need the vir pathway
for the best effect to be obtained.
Oncology
Julio Celis (Copenhagen, Denmark) spoke about
the application of proteomics to cancer research.
The inherent challenge in this is detecting the
∼300000 proteins that are encoded by the human
genome (allowing for all the splice variation and
post-translational modiﬁcations). His group is part
of the Danish Initiative for Breast Cancer Pro-
teomics. Breast cancer is the most common cause
of cancer-related death in women worldwide. The
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disease is very heterogeneous, so there is a need
to proﬁle patients to allow for the provision of
corresponding treatment. They aim to ﬁnd markers
for classifying types of histopathology, and patient
stratiﬁcation, for early detection and for moni-
toring progress and response to treatment. They
obtain samples of normal and diseased breast tissue
and lymph node metastases rapidly after mastec-
tomy and make frozen stocks. Fresh tissue proﬁling
(including proteomics, transcriptomics and patho-
logical assays) is done using portions of the same
sample. The normal tissues are used to build up a
proﬁle of normal background, and connective tissue
samples have been proﬁled so that this contaminat-
ing signal can be subtracted from breast tissue data.
They only resort to laser capture microdissection
if they are desperate. They make extensive use of
antibodies to verify the differences seen on the gels
using tissue slides.
Olli-Pekka Kallioniemi (University of Turku,
Finland) discussed the use of microarrays in can-
cer studies. He noted that while microarrays have
successfully been used to classify cancers with-
out knowledge of the underlying biology, which is
good for diagnosis and prognosis, they have only
given a few clues towards cancer mechanisms and
therapies. He argued that no single array platform
can provide the answer to the bottleneck in con-
verting genomics data into new targets for therapy.
He described three key array-based approaches that
his group have applied to cancer research. In the
ﬁrst, traditional expression arrays were combined
with comparative genome hybridization to identify
270 genes whose expression was signiﬁcantly inﬂu-
enced by copy number in breast cancer; all of the
known important breast cancer fell in this group.
They have also used cell-based arrays (arrayed
cells, or arrayed biomolecules overlaid with cells)
to look at the effects of overexpression, or sup-
pression of expression, of selected genes. The third
approach is to use tissue arrays (with up to 1000
tissue samples on an array) to explore prognos-
tic implications. These have been hybridized with
antibodies to discover which cancers are expressing
genes of interest.
Hereditary disease
Han Brunner (University Medical Centre
Nijmegen, The Netherlands) described how many
complex syndromes share overlapping features, but
also have distinctive features, so the question is
whether they are the same condition or not? The
clinicians who ﬁrst described these syndromes were
either ‘lumpers’ or ‘splitters’ and debated this
question vigorously. Modern genetics is revealing
that diverse syndromes may be due to mutations
in the same gene. Differences arise from mutations
in different parts of these genes, affecting protein
function or tissue-speciﬁc expression.
The converse situation is when one disease
may be associated with many genes. Fanconi’s
anaemia results from mutations in genes encoding
members of the FA complex, all of which are
involved in DNA replication. This is a common
phenomenon: he estimates that half of genetic
conditions may involve multiple genes for a single
disorder because most proteins are involved in
interactions. Phenotypes deﬁne functional modules,
not genes. Walker–Warburg syndrome comprises
muscular dystrophy, brain malformations and eye
abnormalities; it is the most severe of a spectrum
of diseases. The proteins affected by the mutations
underlying these diseases do not interact directly
but they all act in a single pathway governing
O-mannosylation.
Andrea Ballabio (Telethon Institute of Genet-
ics and Medicine, Italy) described deﬁciencies
in the activities of speciﬁc sulphatases that result
in several types of human disease. Ichthyosis is
an X-linked recessive disorder that manifests as
scaly skin. The steroid sulphatase gene respon-
sible was cloned in 1987; 85% of patients have
deletions in this gene, some of which span other
genes, resulting in up to six disorders. One is chon-
drodysplasia punctata, which is due to mutation
of another sulphatase gene. There are 14 known
human sulphatases; four of which cluster on the
distal arm of the X chromosome. They have con-
served sequences, especially a cysteine in the cat-
alytic site.
Multiple sulphatase deﬁciency (MSD) is a con-
dition in which the activity of all sulphatases is
seriously reduced. It is caused by a single, auto-
somal recessive gene defect and has a severe
phenotype. The mutation was found in the sul-
phatase modifying factor 1 gene. Mutations in
this gene were found in every patient tested, all
involving a splice site, creating a missense tran-
script. Sulphatases need post-translational modiﬁ-
cation to change the catalytic site cysteine into
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formylglycine. Vertebrates have two genes for sul-
phatase modifying factors but the mutations found
so far are restricted to SUMF1. Recent work has
shown that the sulphatases within a cell compete
for the SUMF activity. This observation is having
a major clinical impact. Previously, patients were
treated with enzyme replacement therapy, but 80%
of sulphatases produced in cell lines are inactive;
addition of SUMF1 restores sulphatase activity.
Daniela Toniolo (San Raffaele Scientiﬁc Insti-
tute, Italy) described animal models for non-
speciﬁc mental retardation. About 2% of the human
population is mentally retarded, with an IQ below
70, and about half of these cases are due to genetic
causes. It may occur as part of syndrome, but
in many patients, mental retardation is the only
clinical manifestation. There is an excess of male
patients; 14 genes linked to mental retardation have
been located on the X chromosome, one of which
is the Gdi1 gene.
GDI1 is a protein involved in the Rab-GDP/GTP
cycle; it binds to inactive Rab-GDP and maintains
it in a soluble, inactive form. In the brain, αGDI
interacts with Rab3 proteins in synaptic vesicle
fusion and neurotransmitter release. She generated
a mouse in which the Gdi1 gene was knocked out.
The mice were viable and fertile and appeared
normal in many behavioural tests. The level of
aggression in male mice was reduced, but the
Gdi knockouts showed normal olfactory abilities
and testosterone levels. The Gdi knockout mice
performed normally in a spatial memory test but
failed in a working memory test. After further
tests, she concluded that the mice were unable to
associate events that were separated by a short time,
due to speciﬁc cognitive deﬁcits in working and
associative memory. Histological analysis showed
that the Gdi knockout mice had a reduced number
of synaptic vesicles. There were sufﬁcient for the
mice to respond to a single stimulus, but the mice
needed a prolonged inter-test interval to replenish
synaptic vesicles before they could respond to the
next test.
Functional Genomics Technologies
Workshops
Proteome and protein–protein interactions
This session was opened by Ivan Lefkovits (Uni-
versity of Basel, Switzerland) who is studying
the proteome of lymphocytes. This is a huge chal-
lenge because an active lymphocyte contains about
40000 mRNA molecules and about 1000000000
polypeptide chains. A single mRNA can give rise
to 44 polypeptide spots on a 2D gel and there
may be 5000 different peptides present in a cell
at a given time. He plans to focus on the rare
proteins that may function under speciﬁc (physi-
ologically unfavourable) conditions. More details
on this work can be found in his review (in this
issue, p. 531–536).
Michael Dunn (Institute of Psychiatry, UK)
described proteomics in another immunological
setting, heart transplantation. At present, there is
no non-invasive test to predict which transplant
patients will reject the donated hearts, either acutely
or chronically. His team are looking for disease
markers directly in plasma using a variety of
techniques, e.g. 2-DGE, LC–MS, protein or anti-
body arrays and a SELDI–MS chip-based assay.
A major problem is the dynamic range, which is
1012 for the plasma proteome: 99% of the pro-
tein mass of plasma comprises only 22 proteins
and all the interesting markers are lost in the other
1%. One approach is to use antibody depletion,
then look at the remaining proteins. His approach is
called REMAP. Proteins from sequential endomy-
ocardial biopsies are analysed by 2-DGE to detect
alterations in expression. These markers are then
examined to see whether they are diagnostic or pre-
dictive for acute rejection. Candidate proteins are
identiﬁed and antibodies are raised against them.
The antibodies are used to detect whether the rejec-
tion markers are present in plasma and, if so,
whether they can be used to monitor acute rejec-
tion. This approach has produced two candidates,
α-tropomyosin and α-crystallin B chain, both of
which show a doubling of concentration in the
plasma of patients experiencing acute rejection.
A similar approach has shown that vimentin,
an intermediate ﬁlament protein from endothelial
cells, acts as a marker for patients at risk of
developing chronic rejection. The anti-vimentin
antibody titre is correlated with survival.
Switching the emphasis to cancer, Pranav
Sinha (Universitatsklinikum Charite, Germany)
explained that there are 110000 drug-resistant
tumours/year in Germany. These arise through the
overexpression of P glycoprotein (which transports
the drug out of the cell), or other enzymes that
conjugate the drug so that it is excreted, or that
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sequester it within the cell so that it cannot reach
its target. He cultured cell lines in the presence of
anticancer drugs to induce resistance, then looked
for altered patterns of protein expression compared
to the parent cell line. Increased concentrations of
several classes of proteins were observed, including
chaperones, creatine kinase and annexin. He also
saw that gastric and pancreatic cancers showed
different protein proﬁles.
Transcriptome
Wilhelm Ansorge (EMBL, Germany) spoke
about the production of a human genome chip. His
team, in collaboration with colleagues at RZPD,
selected the RZPD3 Human Unigene Set and
arrayed these onto a chip; 48000 (∼90%) of them
have been sequence veriﬁed so far. His team took
great care in comparing alternatives for each part of
the process, from surface chemistry, to pin loading
onto the chips, to labelling techniques. They use
standardized experimental conditions and adhere
to the MIAME guidelines, and the bioinformatic
support for the project has been developed in
collaboration with the EBI.
In addition to this whole-genome chip, they
have other projects, such as the stem cell divi-
sion microarray. This array of candidate genes is
screened with RNA from highly puriﬁed human
HSC populations. This is a very challenging task;
many cells are needed to yield enough RNA for
each experiment. Using a pilot chip, they have
optimized their approach, particularly the RNA iso-
lation method, and can now use just 100 ng RNA
per array.
Another goal is to produce a human protein
chip, an antibody array for protein proﬁling, which
would allow the detection of post-translational
modiﬁcations. To produce the antibodies, they
inoculate mice with 8–10 antigens and fuse the
collected B cells with myeloma cells. They obtain
single cell cultures and use an ELISA approach to
verify the antibodies before use on the array.
Franco Pagani (International Centre for
Genetic Engineering and Biotechnology, Italy)
described two new types of disease-causing
mechanism that perturb RNA processing. The ﬁrst
occurs in ataxia-telangiectasia and involves a defect
in an intronic splicing processing element. The
second is an exon-skipping defect observed in
cystic ﬁbrosis. He suggests that splicing regulatory
elements occur throughout introns and allow the
RNA polymerase to jump along, rather than reading
processively. Thus, many polymorphisms deep
inside introns that were thought to be benign may
affect RNA splicing efﬁciency.
Frank Holstege (University Medical Centre
Utrecht, The Netherlands) gave an excellent dis-
cussion of methods for maximizing genome-scale
data. He identiﬁed four challenges: (a) the rate
of generation of hypotheses is faster than the
rate of veriﬁcation; (b) the problem of data qual-
ity, as high-throughput techniques are associated
with high error rates; (c) functional annotation; and
(d) genome annotation. These can be addressed
by integrating information from publicly avail-
able datasets, such as from microarrays, protein
databases and phenotype descriptions.
High-throughput protein interaction data include
many false positives that need to be eliminated.
One method is to compare the interaction data with
expression data; if the mRNAs are co-expressed
spatially and temporally, then it is more likely that
the proteins interact. Using a cosine function to
represent the degree of co-expression, he was able
to discount half of the proposed protein–protein
interactions in a dataset as false positives.
Protein interactions can be used to characterize
unknown proteins. For pairs of proteins, informa-
tion on the ﬁrst was used to predict the function
of the second, which was then tested. By this
approach, he was able to assign a function to 326
uncharacterized yeast ORFs.
Advances in microarrays
Anne-Christine Syv¨ anen (Uppsala University,
Sweden) described how her group use microar-
rays to genotype SNPs. They use a DNA
polymerase-assisted primer extension ‘minise-
quencing’ approach, with primers covalently
attached to the array as a 14 × 14 array of subarrays
of 50 spots. Up to 80 samples can be analysed for
200 primer sets per slide, generating 16000 geno-
types per slide. The minisequencing approach is
sensitive enough to be used for quantitative SNP
detection, and they have been able to detect alle-
les with frequencies below 1% in a pooled sam-
ple. They have recently developed a four-colour
tag microarray system for multiplex genotyping
and quantiﬁcation of SNPs by primer extension,
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in which the tagged products are captured on an
array of complementary tag-oligos.
Ulf Landegren (Rudbeck Laboratory, Swe-
den) spoke about the padlock and proximity probe
systems that have been developed by his group for
in situ and array-based analyses.
Padlock probes can be used to interrogate thou-
sands of SNPs in solution. The products can be
speciﬁcally ampliﬁed, and then identiﬁed using
a tag microarray. This method avoids the cross-
reaction problems of multiplexing using PCR, and
has been selected for use by the US Haplotype Map
project. The proximity ligation system is designed
for measuring protein expression, by generating
speciﬁc reporter DNA sequences that can be ampli-
ﬁed and detected. For more details on this work,
see his review in this issue (p. 525–530).
Ivo Gut (Centre National de Genotypage,
France) discussed the tools available for genomic
epidemiology. His group have a DNA collec-
tion with 100000 samples representing a range
of pathologies. For small-scale studies, they look
for disease-causing SNPs by resequencing candi-
date genes. Once a polymorphism is found and
validated, they switch to high-throughput anal-
ysis. For medium-scale studies, they use Taq-
Man or Ampliﬂuor for SNP genotyping, and for
high throughput they use the GOOD assay with
MALDI–MS detection. Each system has its advan-
tages and disadvantages; they select which one to
use based on those, and use other platforms for
particular purposes.
They have found that some alleles are popu-
lation-speciﬁc, so knowledge of ‘background’ is
important. They often see more than the three com-
mon haplotypes frequently mentioned in other stud-
ies, and he thinks that more SNPs will be needed
for genome-wide studies than is often quoted. They
are also looking at detecting methylation of DNA,
but this needs good calibration curves, as there is a
degree of methylation at any one site, unlike SNPs,
which are absolute.
Model systems and knockout
Christophe Echeverri (Cenix Bioscience, Ger-
many) discussed the use of RNAi screening to
identify a new medicine. His team used RNAi
screening to identify new cell division genes.
Their automated system designed long dsRNA
molecules to target C. elegans genes, using data
from ACeDB, which it updated each time the anno-
tation was updated. The dsRNAs were microin-
jected into worms and F1 early and late embryos,
and larval and adult F1 progeny were moni-
tored using a high-magniﬁcation time-lapse digital
microscope. Their screen covered 99.2% of the pre-
dicted genes and identiﬁed 47 defects. Knockdown
of 9% of the genes resulted in a phenotype, half
of which where early embryonic, with the others
being distributed across the other three stages.
They have carried out a range of assays in
Drosophila, including of mitotic index and signal
transduction. In their latest screen, which took
2 weeks, they have found 19 new components of
the cellular anti-viral and RNAi response.
They have also been working with short dsRNAs
and he claims that with their modiﬁed design
criteria, Cenix have raised the success rate of this
approach from 60% to around 90%.
Thomas Rudel (Max Planck Institute for
Molecular Genetics, Germany) spoke about high-
throughput RNA interference in mammalian cells.
About 30–40% of siRNAs are ineffective in mam-
malian cells and any effects need to be validated,
which makes the approach cost-intensive. They val-
idate their knockdown using real-time quantitative
PCR. Typically, they either see ∼80% knockdown
or it does not work. The next challenge is to
observe the phenotype, there are many assays to
be done, and some phenotypes only show up in
detailed ‘zoomed-in’ tests, hence there is a need
for automated assays and microscopy.
His group is part of a network, the European
Union for RNA Interference Technology (EURIT:
http://www.eurit-network.org), which aims to do
global RNAi screening in mammalian cells. They
have four initial projects, to make a collection of
published siRNAs, to make a library for vector
mediated RNAi (psiRNA), to generate an siRNA
design tool and a platform for collection and
exchange of siRNAs.
Bioinformatics
Alfonso Valencia (Centro Nacional de Biotec-
nologia, Spain) spoke about ways to reconstruct
protein interaction networks. Across a range of
genomes, for ∼40% of genes, we have no clue as to
their function from sequence homology, so we need
to use other information. One way to do this is to
use information on protein–protein interactions. He
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described the SUISEKI information extraction tool,
written by his group, which they applied to PubMed
abstracts to obtain protein names and information
on their protein–protein interactions. This is being
used in collaboration with the EBI to generate a
new interaction database called INTACT. He also
described other approaches to inferring gene func-
tion, including gene neighbourhoods, gene fusions
and co-evolutionary approaches. By verifying pre-
dicted interactions using the literature, he has found
that combining these methods increases the conﬁ-
dence of predictions, and that interactions predicted
independently by three methods are much more
likely to be true.
Pierre-Alain Binz (Swiss Institute of Bioinfor-
matics, Switzerland) discussed issues for bioinfor-
matics in the ﬁeld of proteomics. He pointed out
that when starting a proteomics project it is impor-
tant to think about the questions that you want to
answer before choosing the approach you use. The
technologies available (classical 2DGE, MudPIT,
ICAT and SELDI) produce quite different results.
Bioinformatics can contribute at all stages of the
process, from laboratory information management
systems (LIMS), to signal detection, to data inter-
pretation, to databases. One such tool provided by
the team at SIB is ‘Melanie’, an image analysis
tool for 2D gels, which identiﬁes proteins that vary.
He urged people to think about ‘what is correct?’
There are many mass spectrometry systems and
many search tools, with variable parameters, so
it is quite possible to get different answers from
the same data. He recommends thinking about the
conﬁdence that can be placed in the results, e.g. by
checking to see whether the proteins that have been
identiﬁed should be expressed in the organelle or
tissue under study.
Peer Bork (EMBL, Germany) spoke about
the application of bioinformatics to molecular
medicine. His group have taken a range of
approaches to this, several of which relate to
improving the annotation of protein function. They
use their SMART tool for domain discovery of
genes, which can suggest a function in disease.
Their STRING tool performs context analysis of
genes, including the phylogenetic co-occurrence,
genomic neighbours and gene fusion approaches.
They have used their tools for literature and data
mining (MESHC and MESHD) with MESH terms
for phenotype, and chemistry and GO terms. They
try to extract molecular information and link terms
to terms. This system was applied to 100 known
disease genes, having taken out those papers that
linked the genes to diseases, and was able to
link many of the genes with the right diseases.
G2D is a database of candidate genes that they
have mapped to diseases in this way (Candidate
Genes to Inherited Diseases: http://dove.embl-
heidelberg.de/g2d/).
They have also looked at coding repeats in can-
cer, investigating a link between coding microsatel-
lites and colorectal cancers, in which mismatch
repair mutations are common. The repeats are often
incorrectly replicated, becoming longer or shorter
and resulting in a frameshift in the gene. They
made a genome-wide search for coding microsatel-
lites and then looked for those that were expressed
in cancer cells. They then looked for cancer cell-
speciﬁc products caused by the shifts, as these
might be displayed on the cell surface, because they
are foreign, and so could be an ideal target for anti-
bodies against the cancers. To date, they have ∼30
candidates.
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